Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
262
resultados
Última actualización
24/03/2026 [06:53:00]
Resultados 25 a 50 de 262
Resumen de: WO2026058191A1
Provided herein are ionizable lipids of the following structural formula: (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein values for the variables (e.g., R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, X5, X6, X7, L1, L2, L3, L4, L5, L6, and L7) are as described herein. Also provided are lipid nanoparticles comprising ionizable lipids of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and methods of using the ionizable lipids, e.g., to administer therapy to a subject in need thereof.
Resumen de: US20260078097A1
The present invention relates to novel piperazine compounds, in particular, of formula (I) or formula (II). These piperazine compounds can be used, for example, in lipid nanoparticle compositions for drug delivery and cancer treatments.
Resumen de: US20260078099A1
The present disclosure provides compounds and the preparation methods, lipid nanoparticles, and pharmaceutical compositions thereof. The compound includes at least one structural formula (I-1) and may be provided as a pharmaceutically acceptable salt, prodrug, or isomer. The compounds of the present disclosure increase structural diversity among lipid molecules. The structure of the compounds directly provides biodegradablity. The L1a, L1b, and L1c groups in the compounds can be interchanged with the L2 group, enabling the integration of other molecules such as steroids and peptides for direct and fast screening. This interchangeability expands the functionality of the cationic lipid compounds, allowing for the direct coupling of functional molecules to the lipid compound to expand its functions. The replaceable L groups offer greater flexibility in selecting L1a, L1b, L1c, and L2.
Resumen de: US20260078086A1
Disclosed are compounds useful for delivering therapeutic or immunogenic nucleic acid agents. Further disclosed are nanoparticle compositions having such a compound and methods for treating or preventing a disease or condition.
Resumen de: US20260076907A1
Fusosome compositions and methods are described herein.
Resumen de: US20260078082A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260078012A1
The invention is directed to a composition of metal particles and methods of manufacturing and using the composition in the treatment of microbial infections and cancer. The particles can be nanoparticles having coupled thereto at least one of a surfactant, an antibiotic, and a drug. The particles of the invention achieve enhanced stability, enhanced cytotoxicity, and enhanced antimicrobial activity through novel combinations of metals, surfactants, antibiotics, and drugs.
Resumen de: US20260076882A1
A phosphorous compound such as STMP is used as a cross-linking agent while making a starch nanoparticle in an emulsion process. Negative charge of the nanoparticle is reduced or reversed by adding cations and/or cationizing the starch optionally while forming the nanoparticles. Anionic active agents, such as fluoride or fluorescein, are optionally incorporated into the nanoparticle during the formation process. For example, a fluoride salt can also be used, which promotes the crosslinking reaction while also providing fluoride in the nanoparticle. The retention of both calcium and fluoride in the nanoparticle is improved when both salts are used. Alternatively, the nanoparticle may be used without added calcium and/or fluoride. The nanoparticles may be useful for tooth remineralization, the treatment of dentinal hypersensitivity, to treat caries, or as a diagnostic agent to locate carious lesions.
Resumen de: US20260078219A1
This disclosure is directed to a process for producing a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H (H) or a hydrophobic moiety (C) and a second terminal group modified with a hydrophilic moiety. The polymer can be a modified symmetrically or asymmetrically branched polymers. This disclosure is further directed to a method for producing a polymer having a pre-defined H/C ratio.
Resumen de: US20260078146A1
EphA2 targeting agents developed herein are potent peptide-mimetics with high affinity (Kds 8-20 nanomolar) for the ligand binding domain, called targefrin. Monomeric versions of targefrin act as antagonists while dimeric versions (targefrin-dimer) of the agent cause receptor internalization and degradation via a lysosomal pathway. Hence, targefrin-dimer agents are effective in reducing pro-oncogenic EphA2 levels in cancer cells when used as single agents or in combination with standards of care. Targefrin-dimers can also sensitive cancer cells that developed resistance to EGER or BRAE inhibitors, and potentially other anti-cancer agents. In addition, the dimeric agents can be conjugated with chemotherapy such as paclitaxel to deliver selectively cytotoxic agent to EphA2 expressing cancer cells. Monomeric agents can be linked to chemotherapy via a stable cleavable linker, accumulate the cytotoxic at the tumor, that then would enter the tumor. Novel composition and examples of these applications are reported.
Resumen de: AU2026201537A1
Methods and systems for delivering a very potent vasodilator that has the ability to treat and prevent heart failure including delivering microcapsules containing α-CGRP, which show no toxicity and lowers blood pressure similar to the native peptide, where this new compound could greatly enhance the lifespan 5 of patients suffering from heart failure. eb e b
Resumen de: AU2026201552A1
Abstract The present invention relates to pretomanid in amorphous form. The invention also relates to method of using the same, such as in a method of treating a mycobacterial infection. eb e b
Resumen de: US20260077057A1
Provided is a novel carrier for introducing a nucleic acid such as a siRNA into a cell. The carrier for a nucleic acid of the present invention includes vesicles from a plant in the family Malpighiaceae, and preferably vesicles derived from acerola. A method for administering a nucleic acid according to the present invention includes forming a conjugate of the carrier for a nucleic acid of the present invention and a nucleic acid and administering the conjugate.
Resumen de: US20260077038A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
Resumen de: US20260076920A1
According to some embodiments, a carrier for reducing a likelihood of a pathogen binding to cell structures of a host comprises a core, surface features extending from an exterior surface of the core, wherein the surface features are configured to bind to target areas of cell structures of the host to at least partially block the pathogen from binding to said target areas as a result of competitive inhibition, and a plurality of binding sites along the exterior surface, wherein the binding sites are configured to attract at least one portion of the pathogen, wherein the binding sites are recognizable by the pathogen and are able to be bound by the pathogen, thereby at least partially immobilizing the pathogen and reducing the likelihood of the pathogen binding to target areas of cell structures of the host.
Resumen de: MX2025010416A
The present invention relates to protamine molecules. More specifically, the present invention relates to protamine molecules and their use in delivery of payload molecules.
Resumen de: WO2026056650A1
The present disclosure relates to a nano-delivery carrier and a preparation method therefor. Specifically, the present disclosure relates to an improved nanoscale lipid carrier for nucleic acid delivery or a delivery system thereof. The carrier comprises an ionizable lipid, a helper lipid, a PEGylated lipid, cholesterol, and a cationic lipid. The nano-delivery carrier of the present disclosure solves the problems of low encapsulation efficiency, batch-to-batch inconsistency of artificially mixed particles, high cationic lipid ratio, high lipid-to-drug ratio, and weak immunogenicity in the prior art.
Resumen de: WO2024189572A1
The present invention discloses carriers with an onco-suppressive agent and selectively directed to a tumoral target for the treatment of metastatic melanoma resistant to a target therapy.
Resumen de: WO2026060416A1
The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets sodium-myoinositol cotransporter-1 (SMIT1) or H+- myoinositol transporter (HMIT). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising HMIT, SMIT, and/or SMIT1 (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and/or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.
Resumen de: WO2026060288A1
Disclosed are compounds useful for delivering therapeutic or immunogenic nucleic acid agents. Further disclosed are nanoparticle compositions having such a compound and methods for treating or preventing a disease or condition.
Resumen de: WO2026060224A1
Described herein are engineered extracellular vesicles (EVs) comprising at least one cyclin-dependent kinase (CDK) protein. Also provided are methods using the EVs to treat a wound, e.g., a diabetic wound.
Resumen de: WO2026059836A1
Lipid nanoparticle (LNP) formulations, methods of producing, and methods of use provided. In some cases, a subject LNP includes: (a) an ionizable lipid (e.g., BP lipid 312, LP01); (b) a neutral phospholipid (e.g., DOPE); (c) cholesterol; (d) a pegylated lipid (e.g., DMG-PEG-2000); and (e) a molecular payload. In some embodiments, a subject LNP includes: (a) a cationic lipid (e.g., ADC); (b) an ionizable lipid (e.g., Lipid III-45, ALC-0315); (c) a neutral phospholipid (e.g., DOPE); (d) cholesterol; (e) a pegylated lipid (e.g., DMG-PEG-2000); and (f) a molecular payload.
Resumen de: WO2026059915A1
Compositions and methods are provided of a therapeutic nanoparticle composed of collagenase IV linked via a linker (e.g. cathepsin B cleavable linker) to ferumoxytol (iron oxide). The collagenase IV is key in the composition intended for the breakdown of the tumor wall as the collagenase. Such compositions and methods are aimed at solving at the same time two of the main challenges of current approaches in the treatment of glioblastoma multiforme (GBM) which are low specificity and poor uptake.
Resumen de: WO2026058267A1
The present invention provides a hyperthermia-induced gut microbiome- mediated modulation of the host immune system for the treatment of gastric/ gastric MALT / Duodenum cancer; the said system uses a wild type/ non-pathogenic/ attenuated strain coated with iron oxide nanoparticles to specifically target the cancerous tissue by applying an external field around the gastric tissue the said iron oxide generates heat on bacteria surface and causes lysis of bacteria in the tumor microenvironment; the lysis of bacteria triggers various potent immune activator and cytokines to activate antigen-presenting cells including lymphocytes and macrophages; the said antigen presenting cell further, eliminates cancer cell from the gut microenvironment and eventually clean tumor microenvironment. Additionally, the activated lymphocytes will be antigenic memory against bacterial particles and cancer tissues. Furthermore, the said treatment system does not involve the use of any chemotherapeutic drug or radiation treatment and, thus, precludes undesirable side effects of chemotherapy as well as minimizes toxicity.
Nº publicación: WO2026056856A1 19/03/2026
Solicitante:
BEIJING JITAI LIFE SCIENCES LTD [CN]
METIS TECHBIO CO LTD [CN]
\u5317\u4EAC\u5242\u6CF0\u751F\u547D\u79D1\u6280\u6709\u9650\u516C\u53F8,
\u5242\u6CF0\u79D1\u6280\uFF08\u5317\u4EAC\uFF09\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: WO2026056856A1
Lipid nanoparticles for delivering nucleic acid molecules, compositions comprising the same, and uses of the lipid nanoparticles and compositions in the preparation of a drug or vaccine for treating diseases.
BOPI
Sede Electrónica
